Our Story

We provide personalized nutrition and actionable insights that allow you to live healthier and maintain normal blood sugar levels. Discover surprising food possibilities, while living your life with smarter nutritional and activity choices. We do this by studying your individual biometrics and lifestyle.

The product is based on a five year research conducted by Prof. Eran Segal and Prof. Eran Elinav from the Weizmann Institute of Science in Israel; the research was funded solely by the Weizmann Insitute of Science and upon its completion, the research technology was licensed to DayTwo. The research results were published in the journal Cell and the Research Video can be found here.

Our Team

Board of Directors

Marius Nacht

Board Member, Co-Founder

Marius Nacht is the Anchor Investor L.P. at aMoon and the Chairman of Check Point Software Technologies Ltd. (NASDAQ: CHKP). In 1993, Marius co-founded Check Point, a global pioneer of cybersecurity and the second largest company in Israel in terms of market capitalization. He is widely considered to be one of the founding fathers of the global cybersecurity industry.

Marius also recently co-founded the 8400 Health Network, an NGO fostering cross- sector collaboration to position Israel as a global life sciences leader.

Marius holds a BSc, cum laude, in Physics and Mathematics, from Hebrew University, and an MSc in Electrical Engineering and Communications Systems from Tel Aviv University. He is a graduate of the IDF elite Talpiot technological academy.

Yair Briman

Chairman

Healthcare executive with over 25 years of experience. Served as the global CEO of Healthcare Informatics at Philips, leading various digital health businesses, including HIS, EMR, PACS, Cardiology Informatics, Oncology Informatics, Interoperability, and Advanced Visualization. Prior to that, Yair served as the General Manager of the Advanced Visualization business unit at Philips. Yair was also the co-founder and board member of Sanara Venture, a healthcare investment platform backed by Philips & Teva. Previously, Yair served in key SW development and managerial roles at Intel.

Lihi Segal

CEO, Co-Founder

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo.

For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Zeev Zehavi

Zeev Zehavi is Vice President of Venture Investments for Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and joined in 1999. He is based out of offices in Israel and Belgium. Mr. Zehavi’s background covers an extensive array of health care and related businesses. He spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America. He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years before starting his own consulting business, Pharma Zee, Ltd.

While operating this consultant business for medical device and pharmaceutical start-up companies, Mr. Zehavi initiated contacts with various Johnson & Johnson companies. Mr. Zehavi holds a Bachelor of Science from Hebrew University of Jerusalem and a Master of Business Administration in Marketing and Finance from Tel Aviv University. He is fluent in Hebrew, English, and Arabic.

Yair Schindel

Co-Founder & Managing Partner

Dr. Yair Schindel is the Managing Partner and Co-founder at aMoon Fund since 2016. Previously, Yair served as the founding CEO of the State of Israel’s National Digital Bureau, responsible for digitizing governmental services and stimulating economic growth. As the Chief Digital Officer of the Israeli government, he invested NIS 2 Billion in digital projects with NIS 10.5 Billion return after less than 3 years.

 Yair is the founder of the MAOZ Network, an NGO building collaboration between Israel’s most influential leaders, with over 300 alumni dedicated to building collaboration between the private, social and public sectors. He recently co- founded the 8400 Health Network, an NGO fostering cross-sector collaboration to position Israel as a global life sciences leader. Yair was an executive, investor, or board member in several healthcare startups including OmniGuide, Zebra Medical Vision, and Medisafe.
Yair earned his BSc and MD degrees at Ben-Gurion University and his MBA at Harvard Business School. He served in the IDF for five years and graduated as Chief Medical Officer of the Israeli Navy Seals, known as “Shayetet 13″.

Eric de La Fortelle

Eric is a Venture Partner with Seventure Partners, a Paris-based venture capital investor investing broadly in life sciences (Rx, Dx, medical device) with a specific focus on the human microbiome. Seventure has raised the first fund worldwide dedicated to the microbiome, called Health for Life, in Dec 2015. Eric is a Board member of Mint Solutions BV, Maat Pharma SA, TargEDys SA, A-Mansia Biotech SA, NeurIMM SA and BiomX and is an observer on the Boards of DayTwo and Anaeropharma Science as a representative for Seventure.

Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche’s global function of External Research and Technologies.Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, a post-graduate diploma in biomedicine from IFSBM (Institut Gustave-Roussy), and an MBA (honors) from INSEAD.

Scientific Consultants

Prof. Eran Elinav

Scientific Consultant, MD PhD

Eran is a Professor leading a research group at the Immunology Department of the Weizmann Institute of Science. His group focuses on deciphering the molecular basis of host-microbiome interactions and their effects on health and disease, with a goal of personalizing medicine and nutrition.
Prof. Elinav published over 110 publications, and received several awards for his work, including the 2013 Alon prize, and the 2015 Rappaport prize, awarded annually to one scientist for outstanding accomplishments in the field of biomedical research.

Before joining the Weizmann Institute, Prof. Elinav held an independent research position as a physician-Scientist at the Institute for Gastroenterology and Liver disease at the Tel Aviv Sourasky Medical Center. Prof. Elinav completed his medical doctor’s (MD) degree at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by a clinical internship, residency in internal medicine, and a clinical and research position at the Tel Aviv Medical Center Gastroenterology institute. He received a PhD in immunology from the Weizmann Institute of Science, followed by a postdoctoral fellowship at Yale University School of Medicine.

Prof. Eran Segal

Scientific Consultant, PhD

Eran is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Systems biology. His research focuses on studying the relationship between nutrition, health and gut microbes in human individuals.
Prof. Segal published over 110 publications, and received several awards and honors for his work, including the EMBO young investigator award, the Michael Bruno award, and the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in the field of computational biology. He was recently elected as an EMBO member and as a member of the young Israeli academy of science.

Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York. Prof. Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a PhD. in Computer Science and Genetics in 2004, from Stanford University.

Management

Lihi Segal

CEO, Co-Founder

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo.

For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Yair Briman

Chairman

Healthcare executive with over 25 years of experience. Served as the global CEO of Healthcare Informatics at Philips, leading various digital health businesses, including HIS, EMR, PACS, Cardiology Informatics, Oncology Informatics, Interoperability, and Advanced Visualization. Prior to that, Yair served as the General Manager of the Advanced Visualization business unit at Philips. Yair was also the co-founder and board member of Sanara Venture, a healthcare investment platform backed by Philips & Teva. Previously, Yair served in key SW development and managerial roles at Intel.

Amir Golan

CCO, International

Amir oversees DayTwo’s commercial activity in international markets.
Amir brings a wide range of leadership experience in building and managing commercial teams that drive rapid growth in international markets. Before Joining DayTwo, Amir served as Executive VP of Business Development at Signals Analytics, a technology-driven, Saas company that is funded by Sequoia Capital, where he played a key role penetrating US and European

markets, dramatically expanding the global customer base to over 50 Fortune 1000 companies.
Before joining Signals, Amir was a Co-Founder and Managing Partner at Arazim Agro, an Israeli agritech company. He served as an Intelligence Officer in the Israeli Air Force and as Assistant to the Israeli Defense Attache in Washington DC. Amir holds an MBA from Ben Gurion University.

Davidi Bachrach

COO

Davidi was the VP Product Management, Population Health in Allscripts where he managed the product life cycle from strategic planning and product roadmap to tactical activities, specifying and prioritizing market requirements for the Population Health products. Prior to Allscripts, he was the VP Professional Services for dbMotion Ltd., managed the company enterprise-wide projects in North America,

planning and implementation of dbMotion technologies at customer sites, developing product assimilation methodologies and providing the technical focal point for system integration, customer support and training. He has a BSc degree in Industrial Engineering and MBA degree from the Ben Gurion University in Israel

Aaron Del Duca

VP Microbiome Platform

Aaron has spent 15+ years in the life science tools and technologies sector developing medical devices and services to democratize access to omics information at scale. Most recently, he was VP Technology at DNA Genotek (acquired by OraSure) and launched their Microbiome Program in 2014.

Aaron led that division through 5 years of triple digit growth and expanded it through M&A (CoreBiome, Diversigen) to include lab and computational services. Aaron has a degree in molecular biology from McMaster, studied Autism Genetics at Queen’s and has had the privilege to help grow companies recognized as Technology Pioneers by the World Economic Forum.

Tal Ofek

VP Projects

Tal has many years of professional experience in Project Management in a variety of fields, Business Development and Regulation. In her position at DayTwo, Tal is responsible for managing and leading projects at the core of the company’s operations. Prior to joining DayTwo, she worked in a variety of positions, both in the public and private sectors.

She led and managed projects in the field of renewable energy within the FK Group international business operations, served in key regulatory and licensing roles in the Ministry of Communications and provided research and consulting services to government offices and various business entities. In 2005, Tal was selected as the Israeli Fellow for the Eisenhower Fellowships Multinational Program. She holds a Ph.D in law from Oxford University, England.

CFO

Shaul Sharoni

Shaul brings over 20 years of leadership roles in finance and operations, driven by a desire to improve processes and outcomes. with a record of leading teams to over-achieve goals in a highly competitive medical device arena. Applies strategic, consultative, and solution tactics while changing business approaches. Skilled at building and leading fund-raising rounds (incl. IPO on TASE). Strong track record of success in leading and growing the accounting and finance functions.

Noa Green

VP Product

Noa has 15 years of experience in product management, specializing in data and mobile products, B2C and B2B2C. Prior to DayTwo, she worked as a Product Manager at Copilot.cx, a Startup enabling Consumer Electronics companies to rely on smart segmentation to improve the customer journey and lifetime value for users.

In her previous roles, she managed the product group and user experience characterization at Zamingo, which provides product strategy consulting, user research and user experience characterization for leading companies in the US and Israeli markets. Additionally, she managed leading mobile products as part of Orange’s innovation unit and took part in the creation of novel products in the US market as part of a startup in 2004.

Adi Lev

VP R&D

Adi brings 20 years of experience in the worlds of Software Development and expertise in the domain of Data Analytics, from enterprise (Intel) and leading mid size companies (Optimal plus, Cellebrite) to top innovative startups (RapidAPI).

As an executive VP and R&D director during the last 10 years, Adi holds a proven record of designing software architecture for complex cloud based and SAAS solutions, as well as with building and managing large, highly effective and fast growing R&D teams, while utilizing best in class engineering flows and practices. Adi holds a BSc in Information Systems Engineering from Ben Gurion University.

Ayelet Ribak

Global VP HR

Ayelet brings over 20 years of Business operations HR experience, serving in several senior HR positions in SMB Hitech/start-ups and as an external consultant. Ayelet has developed a strong methodology that helps businesses analyze their resources in order to better utilize it to meet their business goals/targets.

This analysis together with her deep understanding of operational and organizational needs from this unique angle enables companies to better adjust to dynamic business requirements. Ayelet specializes in Operational Strategy, Business Process definition and integration, merges and acquisitions, HR and Operational Due Diligence processes and integration, company culture, talent acquisition and managerial coaching.

Josh Stevens

CCO, GM USA

Over the past 25 years, Josh has operated and invested in both public and private growth companies in the CRM, EMR, and health benefits administration categories. Josh is an active advisor and investor in early-stage health companies that support outcomes-based-care in diagnostics, chronic-condition-management, and billing & reimbursement services.

Prior to DayTwo, Josh was CEO of Keas (acquired by Welltok), a healthcare SaaS company, that provided health benefits administration to employers and their employees. Prior to Keas, Josh was CRO for YouSendIt (Hightail) and prior to YouSendIt, Josh served and Chief Strategy & Revenue Officer for TicketsNow (acquired by Ticketmaster). Prior to working in early stage companies, Josh spent a decade at AOL where he was General Manager of eCommerce, after having served five years in Corporate Development. Josh started his career on Wall Street in corporate finance at the Chase Manhattan Bank.
In his free time, Josh serves on the Presbyterian Board of Pensions, and for 25 years Josh has also served as a coach for the Special Olympics

Advisory Board

Prof. Ari Shamiss

Prof. Ari Shamiss is the CEO of Sheba General Hospital, a 1400 bed acute care medical center in Israel. Prof. Shamiss holds MD from the Technion Institute and MPA from Harvard University. He is certified in Internal Medicine, Hypertension and Healthcare Management and he is a Professor in Tel Aviv University on these disciplines with more than 60 published scientific papers.Prof. Shamiss was the Surgeon General for the Israel Air Force (Col. Ret.) and the Director of its Aeromedical Institute and he is a graduate in excellence of the US Navy Aerospace Medical Institute.Prof.

Shamiss is involved in numerous global business projects including healthcare technologies, healthcare management services and infrastructure, investment consultancy, Healthcare Information Technology, homeland security, and emergency preparedness. (Apr 2016)

Steven Schwartz

As Senior Vice President, Strategy and Corporate Development at Healthways [Nasdaq: HWAY], Steve is responsible for company strategy, management of emerging businesses, as well as growth via partnerships, and M & A. Steve has more than 25 years of experience in building high-growth companies in healthcare and information technology, joining Healthways from Silicon Valley’s 23andMe. As VP of Business Development and Strategy at 23andMe he was instrumental in accelerating the company’s business-to-business growth

strategy with life sciences companies, health systems, health plans, and retailers. Steve has been a leading innovator and evangelist in the application of information technology in healthcare; from the adoption of mobile technologies, medical records, and giving consumers access to their data; to the use of big data and genomics in drug development and clinical decision support. Prior to 23andMe, Mr. Schwartz was Senior Vice President of Business Development at Allscripts, where he helped lead the company’s dramatic growth for more than a decade, securing strategic partnerships with some of the world’s leading information technology and life sciences companies. Schwartz also spent more than 10 years at LabCorp, contributing to its emergence as the nation’s leading clinical laboratory companies.

strategy with life sciences companies, health systems, health plans, and retailers. Steve has been a leading innovator and evangelist in the application of information technology in healthcare; from the adoption of mobile technologies, medical records, and giving consumers access to their data; to the use of big data and genomics in drug development and clinical decision support. Prior to 23andMe, Mr. Schwartz was Senior Vice President of Business Development at Allscripts, where he helped lead the company’s dramatic growth for more than a decade, securing strategic partnerships with some of the world’s leading information technology and life sciences companies. Schwartz also spent more than 10 years at LabCorp, contributing to its emergence as the nation’s leading clinical laboratory companies.